Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12-50
SponsorWeill Medical College of Cornell University

About this trial

Friedreich's ataxia (FRDA) is an autosomal recessive disease characterized by loss of coordination and cardiomyopathy. It is the most common form of inherited ataxia with an incidence in 1/50,000 in the Caucasian population. FRDA is associated with progressive damage to the nervous system, resulting in symptoms ranging from gait disturbance to speech problems, as well as diabetes and heart disease. The heart disease manifests as cardiomyopathy, and is responsible for approximately 60% of deaths from FRDA. This study is designed to characterize the cardiac manifestations of the disease using exercise, MRI, ECHO and serum parameters, in the context of the neurological disease. In addition, this study will demonstrate that corneal confocal microscopy (CCM) may also provide a biomarker for FRDA.

Eligibility criteria

Qualifiers

Males and females, age 12 to 50

Willing and able to provide informed consent (adolescents will need to provide assent and a parent to provide consent)

Definitive diagnosis of FRDA, based on clinical phenotype and genotype

Left ventricle ejection fraction measured by ECHO of >35% (If results of an ECHO are not available for a potential subject, then an ECHO will first be performed and subjects with an LVEF <35% will not be required to perform the CPET)

Disqualifiers

Signs and symptoms of cardiac failure

Moderate to severe atrial or ventricular arrythmias

History of angina pectoris

Implanted pacemaker and/ or defibrillator or any other device that would preclude MRI assessment

Trial design

Treatments tested in this trial

  • Cardiac magnetic resonance imaging (CMR)
  • Exercise-stress test
  • Echocardiogram (ECHO)
  • Cardiac-related blood studies

Treatment groups

100 Participants
are divided into 2 treatment groups